Prospects for introducing deferiprone as potent pharmaceutical antioxidant

Area of Science:

• Biochemistry
• Pharmacology
• Oxidative Stress Research

Background:

• Free radical formation, often initiated by iron and copper, causes oxidative stress and tissue damage (FRD).
• Natural antioxidants are frequently ineffective in preventing FRD.
• Chelating agents show potential in inhibiting free radical reactions and toxicity.

Purpose of the Study:

• To evaluate the efficacy of chelating drugs, specifically Deferiprone (L1), as novel antioxidant therapies.
• To assess L1's effectiveness in reversing oxidative stress-related tissue damage in various conditions.

Main Methods:

• In vitro and in vivo experimental models.
• Clinical data analysis.
• Assessment of L1's ability to inhibit iron and copper-catalyzed free radical reactions.

Main Results:

• Deferiprone (L1) demonstrated effectiveness and safety in reversing oxidative stress-related tissue damage.
• L1 proved effective in both iron-loading and non-iron-loading conditions, including cardiomyopathy, acute kidney disease, and Friedreich ataxia.
• L1 exhibits a high therapeutic index and can access both extracellular and intracellular compartments.

Conclusions:

• Chelating drugs, particularly L1, represent a promising new strategy for antioxidant therapies.
• L1 is identified as a potent drug antioxidant due to its broad tissue penetration and ability to inhibit metal-catalyzed free radical reactions.
• The selection and combination of chelating drugs could be further explored for enhanced antioxidant treatment approaches.